Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | integrin alpha-ps | 0.0614 | 0.1181 | 0.1678 |
Loa Loa (eye worm) | hypothetical protein | 0.0565 | 0.1056 | 0.0575 |
Echinococcus multilocularis | integrin alpha ps | 0.1179 | 0.2629 | 0.5231 |
Echinococcus granulosus | integrin alpha ps | 0.0565 | 0.1056 | 0.1733 |
Echinococcus multilocularis | integrin alpha ps | 0.1179 | 0.2629 | 0.5231 |
Schistosoma mansoni | integrin alpha-ps | 0.1179 | 0.2629 | 0.4011 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.199 | 0.4707 | 0.7187 |
Schistosoma mansoni | integrin alpha | 0.2631 | 0.6349 | 1 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0178 | 0.0062 | 0.5 |
Echinococcus granulosus | integrin alpha ps | 0.1179 | 0.2629 | 0.5231 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.2631 | 0.6349 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2066 | 0.49 | 0.4626 |
Leishmania major | lanosterol synthase, putative | 0.0153 | 0 | 0.5 |
Echinococcus multilocularis | integrin alpha 3 | 0.2017 | 0.4775 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1451 | 0.3326 | 0.2968 |
Echinococcus multilocularis | integrin alpha ps | 0.0565 | 0.1056 | 0.1733 |
Echinococcus granulosus | integrin alpha 3 | 0.2017 | 0.4775 | 1 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0178 | 0.0062 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0614 | 0.1181 | 0.0707 |
Schistosoma mansoni | hypothetical protein | 0.0565 | 0.1056 | 0.1477 |
Loa Loa (eye worm) | hypothetical protein | 0.199 | 0.4707 | 0.4422 |
Trypanosoma brucei | lanosterol synthase | 0.0178 | 0.0062 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 54.6 % | Vasorelaxant activity against KCl-induced contraction in Wistar rat aorta at 10 ug/ml | ChEMBL. | 17547457 |
IC50 (functional) | > 40 uM | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay | ChEMBL. | 20402524 |
IC50 (functional) | > 40 uM | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay | ChEMBL. | 20402524 |
IC50 (functional) | > 40 uM | Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay | ChEMBL. | 20402524 |
IC50 (functional) | > 40 uM | Cytotoxicity against human U937 cells after 48 hrs by MTT assay | ChEMBL. | 20402524 |
IC50 (functional) | = 46.2 uM | Vasorelaxant activity against KCl-induced contraction in Wistar rat aorta | ChEMBL. | 17547457 |
IC50 (ADMET) | = 87.8 uM | Cytotoxicity against human HeLa cells by MTT method | ChEMBL. | 17547457 |
IC50 (ADMET) | = 87.8 uM | Cytotoxicity against human HeLa cells by MTT method | ChEMBL. | 17547457 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.